Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Armand

Showing results (1-10 of 205) with videos related to

Pageof 21
Sort By:
Bulletin Du Cancer|January 1, 1990
[Navelbine. Current and perspective aspects. International congress of Biarritz (November 1989)]J P Armand
Bulletin Du Cancer|June 17, 2000
[The Bezwoda affair]J P Armand
Japanese Journal of Cancer Research : Gann|August 1, 1994
CPT-11: a novel antitumor drugJ P Armand
Seminars in Oncology|February 1, 1996
CPT-11: clinical experience in phase I studiesJ P Armand
Anti-Cancer Drugs|August 1, 1996
The clinical rationale for developing docetaxel (Taxotere)J P Armand
Annales Pharmaceutiques Francaises|April 2, 2005
[Anti-angiogenic agents in cancerology: myth or reality?]J-P Armand
Revue De L'Infirmiere|November 1, 1981
[New anticancer chemotherapy]J P Armand
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 15, 2000
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?J P Armand
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1997
New anticancer drugs in EuropeJ P Armand
Chinese Medical Journal|April 1, 1997
New anticancer drugs in EuropeJ P Armand
Pageof 21

Showing results (1-10 of 205) with videos related to

Sort By:
Pageof 21
Bulletin Du Cancer|January 1, 1990
[Navelbine. Current and perspective aspects. International congress of Biarritz (November 1989)]J P Armand
Bulletin Du Cancer|June 17, 2000
[The Bezwoda affair]J P Armand
Japanese Journal of Cancer Research : Gann|August 1, 1994
CPT-11: a novel antitumor drugJ P Armand
Seminars in Oncology|February 1, 1996
CPT-11: clinical experience in phase I studiesJ P Armand
Anti-Cancer Drugs|August 1, 1996
The clinical rationale for developing docetaxel (Taxotere)J P Armand
Annales Pharmaceutiques Francaises|April 2, 2005
[Anti-angiogenic agents in cancerology: myth or reality?]J-P Armand
Revue De L'Infirmiere|November 1, 1981
[New anticancer chemotherapy]J P Armand
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 15, 2000
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?J P Armand
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 1, 1997
New anticancer drugs in EuropeJ P Armand
Chinese Medical Journal|April 1, 1997
New anticancer drugs in EuropeJ P Armand
Pageof 21